For the quarter ending 2026-03-31, SLN made $422K in revenue. -$14,957K in net income. Net profit margin of -3544.31%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 422 | 97* | 159 | - |
| Cost of sales | 11 | 38* | 64 | - |
| Gross profit | 411 | 59* | 95 | - |
| Research and development costs | 9,122 | 8,955* | 20,544 | - |
| General and administrative expenses | 7,026 | 2,126* | 5,795 | - |
| Restructuring charges | - | 1,324* | 0 | - |
| Operating loss | -15,737 | -12,345* | -26,244 | - |
| Foreign currency gain/(loss), net | -482 | -301* | 1,934 | - |
| Other income, net | 571 | 1,170* | 770 | - |
| Benefit from r&d credit | 691 | -286* | 2,583 | - |
| Loss before income tax expense | -14,957 | -11,762* | -20,957 | - |
| Other r&d costs | - | - | - | 936 |
| Contracted development costs | - | - | - | 12,232 |
| Personnel research and development costs | - | - | - | 4,479 |
| Income tax expense | 0 | 8* | 1 | - |
| Net loss | -14,957 | -11,770 | -20,958 | -27,354 |
| Basic EPS | -0.11 | -0.083 | -0.15 | -0.19 |
| Diluted EPS | -0.11 | -0.083 | -0.15 | -0.19 |
| Basic Average Shares | 141,702,578 | 141,702,179 | 141,701,848 | 141,696,047 |
| Diluted Average Shares | 141,702,578 | 141,702,179 | 141,701,848 | 141,696,047 |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)